Statin Therapy as Primary Prevention for Persons With HIV: A Synopsis of Recommendations From the U.S. Department of Health and Human Services Antiretroviral Treatment Guidelines Panel

Initiating statin therapy among people with HIV (PWH) with a 10-year atherosclerotic cardiovascular disease (ASCVD) risk score of 5% or higher, whose absolute benefit from statins in REPRIEVE was greatest.

For patients with a 10-year ASCVD risk score below 5%, the Panel favored statins but recommended patient-clinician risk discussions considering additional HIV-related factors that can increase ASCVD risk.